Lupus (SLE): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CD19 80
• BCMA 38
• STING 0
• CD20 9
• SGLT2 3
• STAT3 0
• NLRP3 0
• mTOR 0
• JAK 0
• TNF 0
• IL-17 1
• IL-6 0
• PI3K 0
• CD40 0
• TYK2 0
• CTLA-4 0
• FOXP3 0
• PD-1 0
• PPAR 0
• AMPK 0
• CD38 1
• IL-1 0
• NRF2 0
• TP53 0
• AKT 0
• AQP4 0
• CD22 1
• CXCR4 0
• IL-23 0
• APOL1 0
• BRD4 0
• BTK 0
• CTNNB1 0
• GPX4 0
• HIF-1 0
• HMGB1 0
• IL-15 1
• MAPK 0
• PD-L1 0
• SIRT1 0
• TIGIT 0
• TLR4 0
• ACE2 0
• ANGPTL3 0
• BCL-2 0
• CD123 0
• COX-2 0
• DPP-4 0
• ERK 0
• EZH2 0
• FGFR 0
• FTO 0
• G6PD 0
• GLP-1 0
• IDO1 0
• IL-4 0
• KRAS 0
• LAG-3 0
• MDM2 0
• METTL3 0

1792 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Metabolic microenvironments in humoral immunity (MicroMeta)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, Egyesült Királyság· EU contribution 1 990 728 EUR· until 2031. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Early and sensitive detection of renal involvement and treatment responses in lupus patients using non-invasive biomarkers (EARLINESS)

  Fundacion Publica Andaluza Progreso y Salud M.p.· Sevilla, Spanyolország· EU contribution 226 441 EUR· until 2027. szept.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Understanding the Interaction of T cells and Immune Complexes in Systemic Lupus Erythematosus (TICI-SLE)

  Charite - Universitaetsmedizin Berlin· Berlin, Németország· EU contribution 265 648 EUR· until 2027. aug.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  SInGle cells iN AuToimmUne inflammatoRy disEases (SIGNATURE)

  Fundacion Publica Andaluza Progreso y Salud M.p.· Sevilla, Spanyolország· EU contribution 2 630 239 EUR· until 2026. dec.· 7 countries

4 of 4 running projects, newest first. Listed amounts together: 5,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

  NCT05268289· Novartis Pharmaceuticals· Frissítve: 2026. nov. 12.

  “The decision to conclude the study after Part 1 LPLV is based on strategic considerations by the Sponsor.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus

  NCT05504187· Kira Pharmacenticals (US), LLC.· Frissítve: 2026. nov. 9.

  “Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

  NCT07361094· Beijing Boren Hospital· Frissítve: 2026. okt. 15.

  “No participants.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus

  NCT06943937· China Immunotech (Beijing) Biotechnology Co., Ltd.· Frissítve: 2026. okt. 14.

  “Sponsor decision to discontinue; the study is no longer being pursued due to sponsor strategic reprioritization and resource allocation. The decision was not based on safety concerns. Enrolled participants will complete safety follow-up per protocol.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases

  NCT07583030· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Frissítve: 2026. okt. 2.

  “pipeline strategy change”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus

  NCT07083349· Base Therapeutics (Shanghai) Co., Ltd.· Frissítve: 2026. szept. 30.

  “poor accrual”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

  NCT06342960· Kyverna Therapeutics· Frissítve: 2026. aug. 31.

  “Study discontinued due to sponsor decision.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)

  NCT06984341· Genentech, Inc.· Frissítve: 2026. aug. 5.

  “Decision of Sponsor.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease

  NCT06935474· AbelZeta Inc.· Frissítve: 2026. júl. 16.

  “Sponsor decision to discontinue development and pursue an alternative clinical development strategy”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

  NCT05000216· National Institute of Allergy and Infectious Diseases (NIAID)· Frissítve: 2026. jún. 10.

  “The study was closed due to continued enrollment hurdles.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

  NCT06576271· GlaxoSmithKline· Forrás

• Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

  NCT05268289· Novartis Pharmaceuticals· Forrás

• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  NCT03816345· National Cancer Institute (NCI)· Forrás

• A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  NCT07409181· Boehringer Ingelheim· Forrás

• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

  NCT04963296· Hoffmann-La Roche· Forrás

• A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]

  NCT07840287· EMD Serono Research & Development Institute, Inc.· Forrás

• A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

  NCT07430306· AstraZeneca· Forrás

• Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

  NCT07691970· AstraZeneca· Forrás

• Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

  NCT06133972· Novartis Pharmaceuticals· Forrás

• Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus

  NCT05504187· Kira Pharmacenticals (US), LLC.· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 33
• Mendelian Randomization Analysis 42
• CRISPR-Cas Systems 1
• Gene Expression Profiling 102
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 5
• Proteomics 35
• Metabolomics 23
• Mass Spectrometry 5
• Flow Cytometry 35
• Immunohistochemistry 8
• Liquid Biopsy 2
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 4
• Magnetic Resonance Imaging 49
• Machine Learning 38
• Deep Learning 3
• Cohort Studies 112
• Genome-Wide Association Study 55

• Multi-omics profiling identifies a putative Akkermansia-HK3-lactate immunometabolic link associated with JPZS treatment in lupus nephritis.

  Front Immunol, 2026. okt.

• Untargeted serum metabolomics in systemic lupus erythematosus reveals candidate metabolomic signatures associated with clinical phenotypes and glucocorticoid use.

  Front Immunol, 2026. okt.

• Integrated metabolomics and DNA methylation signatures and their association with flare remission in SLE.

  Lupus Sci Med, 2026. szept.

• A novel urinary metabolic signature for the non-invasive screening of lupus nephritis in systemic lupus erythematosus.

  Clin Chim Acta, 2026. júl.

• Metabolic signatures in systemic autoimmune diseases: A state-of-the-art overview of systemic lupus erythematosus, primary Sjögren's syndrome, and systemic sclerosis.

  Autoimmun Rev, 2026. máj.

• Serum lipidomic and metabolomic signatures link epicardial adipose tissue to cardiovascular diseases in SLE: a post-hoc analysis.

  Lupus Sci Med, 2026. ápr.

• Unveiling Endotypes in Systemic Lupus Erythematosus Through Multiomic Analysis: Insights Into Cardiovascular and Renal Complications.

  Arthritis Rheumatol, 2026. ápr.

• Multiomics-guided discovery of protective microbiome signatures in lupus-prone mice treated with Faecalibacterium prausnitzii.

  Nat Commun, 2026. ápr.

• Integrated metabolomic and cytokine profiling reveals biomarkers across the clinical spectrum of lupus nephritis.

  Front Immunol, 2026. márc.

• Plasma exosomal fibroblast activation protein: a novel biomarker links fatty acid metabolic dysregulation to systemic lupus erythematosus.

  Arthritis Res Ther, 2026. márc.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.